araag2/HINT huggingface dataset:
Clinical trial NCT01119950 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: nva237 12.5 µg once daily, nva237 25.0 µg once daily, nva237 12.5 µg twice daily, nva237 50.0 µg once daily, nva237 25.0 µg twice daily, nva237 100.0 µg once daily, nva237 50.0 µg twice daily, placebo to nva237 once daily
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients age 40 years or more

          -  Diagnosis of Chronic Obstructive Lung Disease (COPD) (moderate to severe as classified
             by the Global Initiative for COPD (GOLD) Guidelines, 2008

          -  Smoking history of at least 10 pack-years

          -  Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) <80% and ≥30% of the
             predicted normal value

          -  Post-bronchodilator FEV1/Forced Vital Capacity (FVC) <0.7

          -  Symptomatic patients, according to daily electronic diary data between visit 2 (Day
             -8) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7
             days prior to visit 3

        Exclusion Criteria:

          -  Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or
             antibiotics and/or hospitalization in the 6 weeks prior to the first visit

          -  Patients who have had a respiratory tract infection within 4 weeks prior to the first
             visit

          -  Patients with concomitant pulmonary disease

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions

          -  Patients with a history of asthma or a blood eosinophil count >600/mm3 or onset of
             symptoms prior to 40 years

          -  Patients with eczema, known high IgE levels or a known positive skin prick test

          -  Patients participating in the active phase of a pulmonary rehabilitation programme

          -  Patients contraindicated for the treatment with anticholinergics, long and
             short-acting beta-2 agonists or sympathomimetic amines

          -  Patients with a history of alpha-1 anti-trypsin deficiency

          -  Patients on long term oxygen therapy (>15hr per day)

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00511706 (phase 2, status: completed)
Conditions: choroidal neovascularization, age-related maculopathy
ICD codes: H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  50 years of age or older with subfoveal choroidal neovascularization (CNV) (classic
             and/or occult) secondary to AMD

          -  Visual Acuity between 20/40 and 20/400 in the study eye

        Exclusion Criteria:

          -  Any intraocular surgery within 3 months

          -  Glaucoma

          -  Cataract

          -  High eye pressure

          -  Uncontrolled systemic disease
Clinical trial NCT00115518 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically verified NSCLC

          -  Not eligible for Radiochemotherapy or patient refuses chemotherapy

          -  FeV1 >1.5 L or min. 50%

          -  KPI >= 70%

          -  Life expectancy > 6 months

          -  Weight loss less than 10% of body weight in 12 months

          -  Compliance

          -  Adequate blood counts (LC > 3000 x 10^3/ml, Tc >100000 x 10^3/ml, Hb > 10 g/dl)

          -  Effective contraception

        Amendment 1/07: FeV1 >1.2 L or min 40%

        Exclusion Criteria:

          -  Active infection

          -  Reduced liver function

          -  Vena cava superior syndrome

          -  Malignant pleural effusion

          -  Pregnancy or breast feeding

          -  Additional serious systemic disease

          -  Secondary malignancy (except carcinoma in situ of the cervix, basalioma of the skin,
             secondary cancer in remission for > 5 years)

          -  Known allergies against proteins

          -  History of former antibody therapy

          -  Allergy against i.v. contrast agents
Clinical trial NCT00621023 (phase 2, status: completed)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: decitabine, arsenic trioxide and ascorbic acid
SMILES: [H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Established diagnosis of MDS (de novo or secondary) fitting either the French American
             British Cooperative Group (FAB) or World Health Organization (WHO) classification
             systems as determined by a complete blood count (CBC) and bone marrow biopsy. Patients
             with >20% bone marrow blasts but <30% bone marrow blasts who would be classified as
             refractory anemia with excess blasts (RAEB-t) in the FAB and acute myeloid leukemia
             (AML) in the WHO systems are still eligible for this study. Patients with low risk MDS
             (IPSS scores low or intermediate -1 (INT-1) must be transfusion dependent to be
             eligible. Transfusion dependent will be defined as having 2 or more transfusion events
             within a 90 day period.

          -  Eastern Oncology Cooperative Group (ECOG) or WHO performance status of 0-2 (Appendix)

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  Pregnant females

          -  AML defined as > 30% bone marrow blasts.

          -  Any malignant disease within the past 2 years, except cervical carcinoma, basal cell
             carcinoma of the skin, and squamous cell carcinoma of the skin..

          -  Off all prior treatment for MDS for at least 4 weeks from entry.

          -  Off any investigational agents for at least 4 weeks from entry.

          -  Uncontrolled cardiac disease or congestive heart failure as defined by New York Heart
             Association criteria of Class III or greater.

          -  Uncontrolled pulmonary disease.

          -  Uncontrolled or active viral or bacterial infection. All infections must have been
             fully treated with antibiotics.

          -  HIV +

          -  Lab values as specified in the protocol
Clinical trial NCT00416598 (phase 2, status: completed)
Conditions: acute myeloid leukemia, acute myeloid leukemia with myelodysplasia-related changes, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22.3;q23.3); mllt3-kmt2a, untreated adult acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: busulfan, cytarabine, daunorubicin hydrochloride, decitabine, etoposide
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, CN(C)\N=N\C1=C(N=CN1)C(N)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Unequivocal histologic diagnosis of AML (> 20% blasts in the bone marrow based on the
             World Health Organization [WHO] and/or French American British [FAB] classifications),
             excluding M3 (acute promyelocytic leukemia); patients with antecedent myelodysplasia
             are eligible for treatment on this trial only if there were no bone marrow biopsy
             showing myelodysplastic syndrome (MDS) > 3 months prior to enrollment; patients with
             therapy-related AML are eligible if they have been free of their primary disease and
             have not received any chemotherapy for at least 2 years

          -  No prior 5-azacitidine or decitabine therapy

          -  No prior treatment for leukemia or myelodysplastic syndrome with four permissible
             exceptions:

               -  Emergency leukapheresis

               -  Emergency treatment for hyperleukocytosis with hydroxyurea

               -  Cranial radiation therapy (RT) for central nervous system (CNS) leukostasis (one
                  dose only)

               -  Growth factor/cytokine support
Clinical trial NCT01273376 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: rx-10100
SMILES: [H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO
Eligibility criteria:

        Inclusion Criteria:

        • Moderate to severe MDD as determined by the DSM-IV-TR Axis 1 Disorders and by the
        Montgomery Asberg Depression Rating Scale (MADRS).

        Exclusion Criteria:

          -  Women who are pregnant, women who will be breastfeeding during the study, and women
             with childbearing potential who are not willing to practice a reliable method of birth
             control

          -  Depressive episode duration of less than 1 month

          -  Lifetime history of any psychotic disorders

          -  Anxiety disorders

          -  Significant suicidality

          -  Clinically significant medical conditions
Clinical trial NCT00392392 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: nab-paclitaxel, bevacizumab, trastuzumab
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients with histologically confirmed adenocarcinoma of the breast or
             inflammatory breast cancer

          -  Clinical stage T 1-4, N 0-3, M0

          -  FISH+ HER2 gene amplified breast cancer

          -  18 years or older

          -  Normal cardiac function

          -  Performance status 0-2

          -  Cannot have received any prior chemotherapy for this disease or cannot have received
             chemotherapy for any other cancer in the past 5 years.

          -  Previous diagnosis of noninvasive breast cancer is OK.

          -  Must have adequate bone marrow, renal and liver function.

          -  Pregnant or lactating females not allowed.

          -  Preexisting peripheral neuropathy must be equal to or less than grade 1

          -  Must have archived tumor tissue for tissue testing.

        Exclusion Criteria:

        You cannot be in this study if you any of the following:

          -  History of cardiac disease, with New York Heart Association Class II or greater with
             congestive heart failure

          -  Any heart attack, stroke or TIAs within the last 6 months or serious arrhythmias
             needing medication; no bleeding diathesis or coagulopathy.

          -  No prior investigational drug within the last 30 days

          -  No prior trastuzumab or bevacizumab therapy

        There are additional inclusion/exclusion criteria. The study center will determine if you
        meet all of the criteria. If you do not qualify for the trial, study personnel will explain
        the reasons.
Clinical trial NCT00529763 (phase 2, status: active, not recruiting)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Signed Written Informed Consent

          -  Men and women, ages 18 years of age or older

          -  Subjects with Chronic Phase (CP) or Advanced Disease (AD) chronic myeloid leukemia
             (CML)/Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)

          -  Subjects resistant/intolerant to imatinib

          -  Subjects presenting:

               1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-2

               2. Adequate hepatic function

               3. Adequate renal function

               4. Sodium, Potassium, Magnesium, Phosphorus, Calcium higher or equal than the lower
                  limit of normal range

        Exclusion Criteria:

          -  Women of child bearing potential who are not using adequate birth control

          -  Women who are pregnant or breastfeeding

          -  Subjects eligible for stem cell transplantation

          -  Serious uncontrolled medical disorder or active infection

          -  Uncontrolled or significant cardiovascular disease

          -  Concurrent incurable malignancy other than CML

          -  Subjects who received imatinib, interferon, cytarabine within 7 days or other
             antineoplastic agents other than hydroxyurea within 14 days before dasatinib,
             Dasatinib in the past

          -  History of significant bleeding unrelated to CML
Clinical trial NCT00453414 (phase 2, status: withdrawn)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: iloprost inhalation solution (ventavis)
SMILES: [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O
Reason stopped: 
    withdrawn due to lack of enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age 3-18 years

          -  Diagnosis of PAH due to IPAH, connective tissue disease, or congenital heart disease

          -  Pulmonary arterial hypertension confirmed by a cardiac catheterization, with mPAP > 25
             mmHg at rest, PCWP or LVEDP ≤ 15 mmHg, and PVR ≥ 240 dynes/sec/cm-5 (ie, ≥ 3.0 units
             m2)

          -  NYHA/WHO functional Class II, III, or IV

          -  Have had a 6-minute walk test (6-MWT) performed within the 3 months preceding the
             screening visit (if ≥ 8 years of age)

          -  Have had cardiopulmonary exercise testing (CPET) performed within the 3 months
             preceding the screening visit (if ≥ 8 years of age and > 130 cms in height. CPET
             testing will be conducted on NYHA/WHO Class IV patients at the discretion of the
             Principal Investigator)

          -  If receiving therapy for PAH, on a stable dose and regimen for at least 3 months prior
             to the screening visit

          -  If receiving digoxin, diuretic, or oxygen therapy, on a stable dose and regimen for at
             least 30 days preceding the screening visit

          -  Must demonstrate the ability to appropriately use the nebulizer device as part of the
             screening process

        Exclusion Criteria:

          -  Prior use of prostacyclins or prostacyclin analogues within 3 months prior to
             screening

          -  Portal hypertension or clinically relevant hepatic disease

          -  Eisenmenger syndrome with resting SpO2 <88% on room air

          -  Clinically relevant asthma or other chronic lung disease, such as bronchopulmonary
             dysplasia, cystic fibrosis, or repaired or unrepaired congenital diaphragmatic hernia

          -  Diagnosis or current evidence of active lung infection or clinically relevant
             hemoptysis

          -  Left-sided heart disease, including valvular disease or heart failure

          -  Initiation or dosage adjustment of PAH-specific therapy within 3 months prior to
             screening

          -  Initiation of treatment with digoxin, diuretics, anticoagulation, or oxygen therapy
             within 30 days prior to screening
Clinical trial NCT00285857 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lovastatin
SMILES: OC(=O)C1=CN=CC=C1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        INCLUSION CRITERIA

          -  Female

          -  Increased inherited risk of breast cancer, as defined by:

               -  Known deleterious mutation in BRCA1, BRCA2, or other high-risk mutation

               -  Family history conveying at least a 2-fold increase in breast cancer risk

          -  ECOG performance status 0

          -  Normal organ and marrow function, including complete blood count and comprehensive
             metabolic panel within normal institutional limits

          -  Subject agreement to limit alcoholic beverage consumption to three alcoholic drinks
             per week.

        EXCLUSION CRITERIA

          -  Prior history of invasive breast cancer less than 2 years previously (EXCEPTION: stage
             III or lower breast cancer > 2 years ago)

          -  Current or history of other cancers (EXCEPTION: non-melanoma skin cancer, or stage III
             or cancer without evidence of recurrence for 5 years

          -  Initial mammogram, breast MRI, or clinical breast examination prompts recommendation
             for biopsy by study investigators.

          -  Evidence of malignant cytology on initial rpFNA.

          -  Use of other investigational agents.

          -  Use of tamoxifen or selective estrogen response modifiers (SERMS), including
             raloxifene, within the last 2 years.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to lovastatin.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac
             arrhythmia; or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Currently receiving lovastatin and cyclosporine, gemfibrozil, erythromycin, fibrates
             or niacin, (unless discontinued for study participation)

          -  No evidence of active liver disease, nor elevation of serum transaminases (prior
             history of liver disease, if not currently active, is not an exclusion)

          -  No evidence of myopathy or myositis, including symptoms of generalized muscle aches or
             weakness, muscle tenderness, or elevation in creatine phosphokinase.

          -  Lactating (breastfeeding)
Clinical trial NCT01011322 (phase 2, status: unknown status)
Conditions: ulcerative colitis, large intestine, diarrhea, abdominal pain
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811, K59.1, R19.7, P78.3, K58.0, K58.9, R10.84, R10.9, R10.10, R10.30
Drugs: lt-02, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women 18 years or older who have given written Informed Consent

          -  Patients with proven ulcerative colitis

          -  Active disease course for the last 6 weeks or longer with bloody diarrhea

          -  Patients with an inadequate response to a treatment with mesalazine or a documented
             intolerance to mesalazine.

        Exclusion Criteria:

          -  Infectious colitis, including cytomegalovirus or Clostridium difficile induced
             colitis,

          -  Crohn's disease,

          -  Colitis due to other reasons than ulcerative colitis like known diverticulitis,
             radiation colitis, ischemic colitis, microscopic colitis, or indeterminate colitis,

          -  Treatment with other investigational medicinal product within 3 months prior to study
             entry
Clinical trial NCT00600249 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cetuximab, docetaxel
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  § Age > or equal to 18 years.§

          -  Performance status inferior or equal to 1 (WHO criteria)

          -  Histologically proven breast cancer, non metastatic, with clinical tumor diameter > or
             equal to 2 cm.

          -  HR negative and HER 2 negative.

          -  Clinical stage II and IIIa.

          -  Non prior treated patients either by surgery, radiotherapy, hormonotherapy or
             chemotherapy.§

          -  Adequate hematological, renal and hepatic functions : neutrophils > 2.109 /L,
             platelets > 100.109 /L, Hb > 10 g/dL, normal bilirubin, ASAT and ALAT inferior or
             equal to 2,5 ULN (upper normal limit), alkaline phosphatases £ 2,5 ULN, creatinine <
             140 µmol/L or creatinine clearance > 60 mL/min.§

          -  Written informed consent§

          -  Affiliation with social security system (or profit being of such a mode) according to
             terms' of the law of August 9, 2004.

        Exclusion Criteria:

          -  Male patient.

          -  Pregnant or lactating women or childbearing potential with no efficacy contraception.

          -  Other breast cancer form and particularly inflammatory form and/or negliged (T4b or
             T4d).§

          -  Non measurable tumor.

          -  Prior surgery or primary axillary dissection.

          -  Prior treatment for this new breast cancer.

          -  Under guardianship patient

          -  Patient with antecedent of second cancer, excepted in situ uterine carcinoma or
             baso-cellular cutaneous cancer considered as definitively cured.

          -  Patient with an associated pathology considered incompatible with the study.§ Cardiac,
             renal, medullar, respiratory or hepatic insufficiency.

          -  Significant neurological or psychiatric troubles.§ Symptomatic or evolutive troubles
             in CNS or metastasis.

          -  Peripheral neuropathy > grade 2 NCI-CTC (version 3.0)

          -  Previous allergy with polysorbate 80.

          -  Concomitant treatment with a drug tested in a clinical trial, participation to another
             clinical study, for the last thirty days or prior chemotherapy.

          -  Patients non stable for the following 6 months or leaving at a great distance of the
             participating center.
Clinical trial NCT00555789 (phase 2, status: terminated)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: aeb071, mycophenolic plus tacrolimus
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion criteria:

          -  Participation in core study CAEB071A2203

          -  The patient has been maintained on AEB071/mycophenolic acid or tacrolimus/mycophenolic
             acid, consistent with their original randomization, at their core study Month 12
             visit.

          -  Women capable of becoming pregnant are required to practice a medically approved
             method of birth control as long as they are on study medication and for a period of 3
             months following discontinuation of study drug(s).

        Exclusion criteria:

          -  Pregnancy. Other protocol-defined inclusion/exclusion criteria may apply